Trials / Completed
CompletedNCT01579084
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-199201 Formulation A | AGN-199201 Formulation A applied to the face as per protocol twice daily. |
| DRUG | AGN-199201 Formulation B | AGN-199201 Formulation B applied to the face as per protocol twice daily. |
| DRUG | AGN-199201 Formulation C | AGN-199201 Formulation C applied to the face as per protocol twice daily. |
| DRUG | AGN-199201 Vehicle | AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2012-04-17
- Last updated
- 2019-11-18
- Results posted
- 2013-11-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01579084. Inclusion in this directory is not an endorsement.